NEW YORK (GenomeWeb) – Swiss proteomics firm Biognosys said today that it has closed a Series C financing round with which it will continue development of its data-independent acquisition mass spec offerings and open a US office.

Biognosys plans to open an office in Boston toward the end of the first quarter of this year, CEO Oliver Rinner told GenomeWeb. The company did not disclose the amount raised in the Series C round or the participating investors, but said the round generated in the "mid-single-digit millions" of dollars.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.